CHEMOGUIDE
Chemotherapy guidance based on efficacy of treatment regimen in cancer cells from the individual patient
| Coordinatore | 2cureX
Organization address
address: Birkevej 37 contact info |
| Nazionalità Coordinatore | Denmark [DK] |
| Totale costo | 1˙597˙720 € |
| EC contributo | 1˙043˙000 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2012 |
| Funding Scheme | CP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-04-01 - 2015-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
2cureX
Organization address
address: Birkevej 37 contact info |
DK (Birkeroed) | coordinator | 426˙160.00 |
| 2 |
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Organization address
address: Martinistrasse 52 contact info |
DE (HAMBURG) | participant | 253˙600.00 |
| 3 |
microLIQUID sl
Organization address
address: Av. Uribarri 19-1 contact info |
ES (Arrasate-Mondragon) | participant | 221˙440.00 |
| 4 |
REGION HOVEDSTADEN
Organization address
address: KONGENS VAENGE 2 contact info |
DK (HILLEROD) | participant | 141˙800.00 |
| 5 |
REGENTS OF THE UNIVERSITY OF COLORADO
Organization address
address: Marine Street - Room 479 3100 contact info |
US (Boulder CO) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The ChemoGuide project will clinically validate a proto-type technology (2treat) developed in the previous “Research for SMEs” project, “Integrated Chemical Synthesis and Cell screening in patient cells (ICSC). The project will execute a clinical study to evaluate the 2treat test’s capability of predicting which combination therapy that is most efficacious and show no resistance in the individual colorectal cancer patient. The prediction is based on reading the cell functional output cancer cells isolated from the individual patient. The clinical study will serve to verify the capability and robustness of the 2treat test. The 2treat test is formatted as an easy-to-use, disposable test array. Colorectal cancer is now the most diagnosed cancer in EU, and the prognosis of especially stage III and IV patients is very poor. The 2treat test is expected to provide a major benefit to these patients by significantly improving the Prognosis Free Survival (PFS). Importantly oncologist will be provided the first technology that is capable of testing the cell-functional output of all combination treatment regimens used for treatment of colorectal cancer in Europe and USA before a first line treatment is launched. The technology will both improve treatment quality for the individual patient and raise the cost efficiency providing a positive impact on the health care systems.'